Navigation Links
AuraSense Therapeutics Closes Tranche II of Series B Equity Investment

SKOKIE, Ill., July 31, 2013 /PRNewswire/ -- AuraSense Therapeutics, a biopharmaceutical company commercializing spherical nucleic acid (SNA™) constructs as gene regulation and modulation agents for a variety of diseases, including applications in oncology, dermatology, neurology, and for immune disorders, has closed the second tranche of its Series B financing.  The investment adds to the initial Series B round completed in December 2011.  Investors in the Series B round include AbbVie, Inc.  Other key individual investors in the round include Patrick Ryan, founder of Aon; David Walt, co-founder of Illumina; Boon Hwee Koh, Director of Agilent Technologies and former Chairman of Singapore Airlines, and Craig Mundie, Chief Research and Strategy Officer of Microsoft.  Terms of the investment were not disclosed.

"It's fantastic to have so many investors from the original consortium come back for this follow-on investment round," said Van Crocker, Vice President of Commercial Development for AuraSense Therapeutics.  "This financing shows the faith our investors have in the technology, the team and our progress to date.  We look forward to taking our first SNA constructs through the preclinical development phase."

Schiff Hardin LLP served as deal counsel to AuraSense Therapeutics for the investment transaction.

About AuraSense Therapeutics, LLC

AuraSense Therapeutics, LLC is a privately held biopharmaceutical company founded by Professors Chad A. Mirkin and C. Shad Thaxton of Northwestern University.  Headquartered in Skokie, Illinois, the Company is dedicated to developing and commercializing spherical nucleic acid (SNA™) conjugates.  Its proprietary SNA constructs possess unparalleled biocompatibility and versatility as therapeutics, and they hold great promise for combating the world's most threatening diseases.  The Company's SNA technology overcomes the most difficult obstacles to gene regulation:  genetic targeting with safe and effective in vivo performance.  For additional information about the company, please visit

SOURCE AuraSense Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Covington Advises Actelion in Acquisition of Ceptaris Therapeutics
2. Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
3. Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
4. Serina Therapeutics Announces Agreement with the Scripps Research Institute for Development of Polymer-Antibody Drug Conjugates
5. Advanced Prenatal Therapeutics Appoints Dr. Nihar Nayak to its Scientific Advisory Board
6. Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614
7. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
8. Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
9. Frost & Sullivan: Molecular Farming Fits Need for Fully Functional Protein Therapeutics and Low-Cost Vaccines
10. Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis
11. Distinguished Cancer Investigator, Daniel Von Hoff, M.D., to Lead Cell Therapeutics Scientific Advisory Board
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused on ... of various clinical conditions, today announced the closing of ... Depository Shares ( ADSs ), each representing 20 ordinary ... to 3,158,900 ADSs. The ADSs and warrants were issued ...
(Date:11/25/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a developer ... Officer Antonius Schuh, Ph.D., is scheduled to present a ... Jaffray Healthcare Conference. th Annual Piper ... in New York on Tuesday, ... will be available for one-on-one meetings during the conference. ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has been recognized once again for its stellar workplace culture with the company’s ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati ...
(Date:11/25/2015)... (PRWEB) , ... November 26, 2015 , ... ... Union Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and ... Office in Nairobi (UNON) for the opening of the 5th African Network for ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... ... , ... On November 23rd 2015 Cozy Products, a division of ... Cozy Products explains what this means for business moving forward. , The Tri Lite ... business model: to sell personal heaters that reduce energy consumption, are economical and keep ...
Breaking Medicine News(10 mins):